文献速递临床试验与 GCP基础与转化研究

四盲随机对照试验:漱口液降低住院COVID-19患者口内病毒载量

A quadruple blind, randomised controlled trial of gargling agents in reducing intraoral viral load among hospitalised COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2020-09-14

本研究为平行组、四盲随机对照预试验,纳入50例轻中度住院COVID-19患者,比较1%过氧化氢、0.2%聚维酮碘、2%高渗盐水及印楝提取物漱口液与蒸馏水对照在降低口内病毒载量及唾液细胞因子方面的效果。主要结局为实时定量PCR确认的口内病毒载量下降。

要点

  • 四盲设计比较四种漱口液与蒸馏水对照的口内病毒载量降低效果。
  • 每例患者漱口和鼻腔冲洗20-30秒,每日三次,持续6天。
  • 主要结局为实时定量PCR确认的口内病毒载量下降。

核心结论

  • 预试验旨在比较1%过氧化氢、0.2%聚维酮碘、2%高渗盐水及印楝提取物漱口液与蒸馏水对照在降低口内病毒载量方面的效果。

研究设计与样本

  • 平行组、四盲随机对照预试验,附加实验室研究,在巴基斯坦卡拉奇阿迦汗大学医院开展。
  • 计划纳入50例实验室确诊COVID-19住院患者,年龄18-65岁,轻中度疾病,按1:1:1:1:1随机分五组,每组10例。
  • 排除格拉斯哥昏迷评分低、放化疗史、症状超过7天、插管或无牙、接受抗病毒治疗或已有慢性黏膜病变者。

主要发现

  • 主要结局为实时定量PCR确认的口内病毒载量下降。
  • 次要探索唾液IL-2、IL-4、IL-6、IL-10、TNF-α、IFN-γ和IL-17细胞因子谱。

关键数值与推荐

  • A组:0.2%聚维酮碘10 ml漱口和鼻腔冲洗20-30秒,每日三次,共6天。
  • B组:1%过氧化氢10 ml漱口和鼻腔冲洗20-30秒,每日三次,共6天。
  • C组:印楝提取物溶液10 ml漱口和鼻腔冲洗20-30秒,每日三次,共6天。
  • D组:2%高渗盐水10 ml漱口和鼻腔冲洗20-30秒,每日三次,共6天。
  • E组:蒸馏水漱口和鼻腔冲洗20-30秒,每日三次,共6天。

临床怎么用

  • 使用后30分钟内不进食、饮水或漱口。
  • 鼻腔冲洗使用专用冲洗注射器,由数据收集员详细说明使用方法。

局限性

  • 因无前期研究,无法进行样本量计算假设,本研究为预试验。
  • 采用非概率目的抽样技术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: 1- To compare the effectiveness of 1% Hydrogen peroxide, 0.2% Povidone-Iodine, 2% hypertonic saline and a novel solution Neem extract (Azardirachta indica) in reducing intra-oral viral load in COVID-19 positive patients. 2- To determine the salivary cytokine profiles of IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ and IL- 17 among COVID-19 patients subjected to 1% Hydrogen peroxide, 0.2% Povidone-Iodine, 2% hypertonic saline or Neem extract (Azardirachta indica) based gargles. TRIAL DESIGN: This will be a parallel group, quadruple blind-randomised controlled pilot trial with an add on laboratory based study. PARTICIPANTS: A non-probability, purposive sampling technique will be followed to identify participants for this study. The clinical trial will be carried out at the Aga Khan University Hospital (AKUH), Karachi, Pakistan. The viral PCR tests will be done at main AKUH clinical laboratories whereas the immunological tests (cytokine analysis) will be done at the Juma research laboratory of AKUH. The inclusion criteria are laboratory-confirmed COVID-19 positive patients, male or female, in the age range of 18-65 years, with mild to moderate disease, already admitted to the AKUH. Subjects with low Glasgow coma score, with a history of radiotherapy or chemotherapy, who are more than 7 days past the onset of COVID- 19 symptoms, or intubated or edentulous patients will be excluded. Patients who are being treated with any form of oral or parenteral antiviral therapy will be excluded, as well as patients with known pre-existing chronic mucosal lesions such as lichen planus. INTERVENTION AND COMPARATOR: Group A (n=10) patients on 10 ml gargle and nasal lavage using 0.2% Povidone-Iodine (Betadiene® by Aviro Health Inc./ Pyodine® by Brooks Pharma Inc.) for 20-30 seconds, thrice daily for 6 days. Group B (n=10) patients will be subjected to 10 ml gargle and nasal lavage using 1% Hydrogen peroxide (HP® by Karachi Chemicals Products Inc./ ActiveOxy® by Boumatic Inc.) for 20-30 seconds, thrice daily for 6 days. Group C will comprised of (n=10) subjects on 10ml gargle and nasal lavage using Neem extract solution (Azardirachta indica) formulated by Karachi University (chemistry department laboratories) for 20-30 seconds, thrice daily for 6 days. Group D (n=10) patients will use 2% hypertonic saline (Plabottle® by Otsuka Inc.) gargle and nasal lavage for a similar time period. Group E (n=10) will serve as positive controls. These will be given simple distilled water gargles and nasal lavage for 20-30 seconds, thrice daily for six days. For nasal lavage, a special douche syringe will be provided to each participant. Its use will be thoroughly explained by the data collection officer. After each use, the patient is asked not to eat, drink, or rinse their mouth for the next 30 minutes. MAIN OUTCOMES: The primary outcome is the reduction in the intra-oral viral load confirmed with real time quantitative PCR. RANDOMISATION: The assignment to the study group/ allocation will be done using the sealed envelope method under the supervision of Clinical Trial Unit (CTU) of Aga Khan University, Karachi, Pakistan. The patients will be randomised to their respective study group (1:1:1:1:1 allocation ratio) immediately after the eligibility assessment and consent administration is done. BLINDING (MASKING): The study will be quadruple-blinded. Patients, intervention provider, outcome assessor and the data collection officer will be blinded. The groups will be labelled as A, B, C, D or E. The codes of the intervention will be kept in lock & key at the CTU and will only be revealed at the end of study or if the study is terminated prematurely. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): As there is no prior work on this research question, so no assumptions for the sample size calculation could be made. The present study will serve as a pilot trial. We intend to study 50 patients in five study groups with 10 patients in each study group. For details, please refer to Fig. 1 for details. TRIAL STATUS: Protocol version is 7.0, approved by the department and institutional ethics committees and clinical trial unit of the university hospital. Recruitment is planned to start as soon as the funding is sanctioned. The total duration of the study is expected to be 6 months i.e. August 2020-January 2021. TRIAL REGISTRATION: This study protocol was registered at www.clinicaltrials.gov on 10 April 2020 NCT04341688 . FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2). Fig. 1 Flow diagram of study-participants' timeline.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Khan FR, Kazmi SMR, Iqbal NT, et al. A quadruple blind, randomised controlled trial of gargling agents in reducing intraoral viral load among hospitalised COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020. PMID: 32928313. doi:10.1186/s13063-020-04634-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。